ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CRDL / financials
MOLN (46) CHRS (29) CMPX (34) TARA (32) ⌘ Pro Terminal →

Cardiol Therapeutics Inc. (Class A) (CRDL) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.04 -6.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.03

Cardiol Therapeutics Inc. (Class A) (CRDL) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $133.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRDL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRDL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Cardiol Therapeutics Inc. (Class A) (NASDAQ: CRDL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.04 (-6.31% 1D, market cap $133.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, CRDL ranks #397 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRDL compare to MOLN and CHRS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDL carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MOLN (Molecular Partners AG) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $134.3M) and CHRS (Coherus Oncology Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $128.3M). Among the 5-stock peer group, CRDL leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRDL?
▼

For Cardiol Therapeutics Inc. (Class A) (CRDL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #397 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.03 (-1.33%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (12)Whales (3)SEC (13)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.7% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE CRDL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRDL)Realized 20D OHLCV Swing Band: ±11.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY CRDL SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($3.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
52
Grade C-$1.18-6.8% Next Q
Q2 (-2Q)
49
Grade D$1.10+1.8% Next Q
Q3 (-1Q)
47
Grade D$1.12-7.1% Next Q
Current
44
Grade D$1.04-6.5% Hist 90D α
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRDL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRDL currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.61) and Max Pain ($1.09) forces dealer call-delta covering toward $2.46.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRDL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRDL Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How CRDL Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$3.8M (0.1% FCF Margin)
Revenue$4.00BGross Profit $2.08B (52%)Cost of Sales $1.92BOp Profit $1.08B (27%)OpEx (R&D/SG&A) $998.4MNet Profit$865.3M (21.6%)Tax/Other $216.3M
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRDL)

  • ✓Walkthrough of CRDL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CRDL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.80%▼ SUPPORT BREAKDOWN
2026-11-03O $1.17H $1.17L $1.04C $1.04VOL 711.7K
RES: $2.85SUP: $1.07SMA50: $1.61SMA200: $1.30
$2.44$2.04$1.64$1.24$0.84RES $2.85SUP $1.07$1.042026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRDL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRDL Butterfly Map → + Track CRDL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CRDL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRDL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRDL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRDL)

Health Care Rank #397 of 1015 ⚔️ MOLN vs CRDL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRDL vs. MOLN, CHRS, CMPX, TARA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cardiol Therapeutics Inc. (Class A) (CRDL) ranks #397 by composite RQD confidence (44/100, grade D) and #618 by equity capitalization ($133.9M). Within this direct 5-issuer industry benchmark cohort, CRDL leads on earnings valuation at N/A trailing P/E, while CMPX leads on capital efficiency and profitability with -34.6% ROIC and — gross margin. MOLN currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CRDL at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CRDL ACTIVE
Cardiol Therapeutics Inc. (Class A)
D 44/100 — — — -6.31% $133.9M Benchmark Subject
MOLN
Molecular Partners AG
D 46/100 — — — -2.79% $134.3M /moln-vs-crdl →
CHRS
Coherus Oncology Inc.
E 29/100 — — -35.0% -9.72% $128.3M /chrs-vs-crdl →
CMPX
Compass Therapeutics Inc.
E 34/100 — — -34.6% -2.42% $141.6M /cmpx-vs-crdl →
TARA
Protara Therapeutics Inc.
E 32/100 — — -34.7% -2.82% $146.6M /tara-vs-crdl →

2. CRDL Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Cardiol Therapeutics Inc. (Class A) (CRDL) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $133.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. CRDL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRDL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cardiol Therapeutics Inc. (Class A) (NASDAQ: CRDL) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $1.04 (-6.31% 1D, market cap $133.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, CRDL ranks #397 in composite RQD confidence.

How does CRDL compare to MOLN and CHRS in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRDL carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MOLN (Molecular Partners AG) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $134.3M) and CHRS (Coherus Oncology Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $128.3M). Among the 5-stock peer group, CRDL leads on earnings multiple (N/A) while CMPX leads on capital efficiency (-34.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRDL?

For Cardiol Therapeutics Inc. (Class A) (CRDL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #397 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRDL trading relative to its 50-day, 200-day, and 52-week technical levels?

CRDL last traded at $1.04 (-6.31% on volume of 740,376 shares), positioning the stock -35.40% below its 50-day simple moving average ($1.61) and -20.00% below its 200-day simple moving average ($1.30). Across its 52-week range of $0.88 to $2.34, CRDL sits at the 11.0% percentile with a 14-day RSI of 29.6 (OVERSOLD (<32)) and an implied next-earnings move of ±11.5% ($1.00 to $1.16).

Direct Sub-Reports: CRDL RQD Cockpit CRDL 12M Forecast CRDL Earnings & Move CRDL Dividends & DRIP CRDL Insiders & 13F CRDL Whale Options CRDL Profit Sankey CRDL News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

CRDL — Cardiol Therapeutics Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cardiol Therapeutics Inc. (Class A) (CRDL) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $1.04 (-6.31% 1D, market capitalization $133.9M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Cardiol Therapeutics Inc. (Class A) (CRDL) operates in the Biotechnology: Biological Products (No Diagnostic Substances) industry (Health Care sector) with an equity capitalization of $133.9M, gross margin of —, operating margin of —, and return on invested capital (ROIC) of —.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.88 – $2.34 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The supply chain is "NONE," with an empty set of butterfly links and no proprietary signals. Sector is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances). Because no upstream or downstream dependencies are mapped, no second-order bottlenecks or sector-correlation effects can be stated from the source data. Investors should note that the absence of mapped links is itself a data gap, not evidence of independence.

  • Key Question #1: Can CRDL sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $2.34 52-week high?
  • Key Question #3: How sensitive is CRDL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CRDL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cardiol Therapeutics Inc. (Class A) (CRDL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRDL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRDL Bull vs. Bear Conversation Board — What's Your Call at $1.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRDL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CRDL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $1.38 (+24.3%)
📌 Pinned Debate

Forensic balance sheet scores 13/20 with Altman Z 2.5 and Piotroski F 6/9, the strongest pillar in an otherwise weak rating.

Here is why I am bullish on CRDL here at $1.11: Forensic balance sheet scores 13/20 with Altman Z 2.5 and Piotroski F 6/9, the strongest pillar in an otherwise weak rating.. Compare CRDL's 0.0% operating margin and 0.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $1.05 are getting bought.

CapAlloc_Nerd 🐂 BULL

@DeltaGamma_99 Agree on the RQD 44/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.11 and keeping dry powder in case we test $1.03.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $0.84 (-24.3%)
Spot @ $1.11

ROIC 0% and FCF yield 0% with an RQD of 52 (D+, Roarable Sell — Weak Fundamentals / Trim) leave no evidenced cash-generation support.

ROIC 0% and FCF yield 0% with an RQD of 52 (D+, Roarable Sell — Weak Fundamentals / Trim) leave no evidenced cash-generation support.. Look at the math on CRDL: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $0.98 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%